Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Anytime Fitness expanding world's largest and fastest-growing fitness club with three new clubs in Hong Kong
2022-06-06 09:00
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
2022-06-06 08:30
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-06-06 08:08
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
2022-06-06 08:00
Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-06-06 08:00
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
2022-06-05 18:30
CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022
2022-06-05 08:02
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
2022-06-04 20:30
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
2022-06-04 08:02
Novo Nordisk South Africa earns the Best Place to Work Certification for the second year in row
2022-06-03 17:51
Jasmine Food emphasizes the importance of well-balanced meals during this Aidilfitri
2022-06-03 10:00
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
2022-06-02 20:08
Manulife provides life insurance to HIV+ individuals as part of its drive to build an inclusive and equitable society
2022-06-02 14:29
Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future
2022-06-02 12:54
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022
2022-06-02 08:08
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares
2022-06-02 08:00
First futures exchange aimed at health care economy has filed for regulatory approval
2022-06-01 19:00
Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific
2022-06-01 18:00
PMB Announces EIT Health Supported FLASHKNiFE Consortium Towards the Clinical Application of FLASH Radiation Therapy
2022-06-01 16:15
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
2022-06-01 16:00
1
198
199
200
201
202
740